41 research outputs found
Effect of Fibrin-binding Synthetic Oligopeptide on the Healing of Full-thickness Skin Wounds in Streptozotocin-induced Diabetic Rats
Introduction
Fibronectin(FN) has many other adhesive sites for various substances, including fibrin, heparin and collagen. The FN subunit contains two fibrin binding sites. Among these two sites, the major site close to the amino terminus serves as a transglutamination site for activated factor XIII, crosslinking FN to various other proteins including fibrin, fibrinogen. In blood clotting cascade, plasma FN-fibrin matrix is covalently cross linked, and then it promotes fibroblast adhesion, spreading, and migration into the clot. However, due to the common shortcomings of whole protein usage, including instability to enzymatic degradation, unexpected effects of other domains, nonspecific binding to other types of cells, difficulty in obtaining a stable attachment, and even integrin blocking effects, small synthetic peptides with active binding sequences of natural proteins have been proposed as alternatives. Based on these findings, we assumed that topical application of fibrin-binding oligopeptides from FN to the soft tissue wound site might compensate the impaired wound healing in diabetes individuals. The aim of this study was to investigate whether topical application of fibrin-binding oligopeptides derived from FN promotes wound healing in streptozotocin (STZ)-induced diabetic rats.
Materials and Methods
Oligopeptides including fibrin-binding sequences (FF3 : CFDKYTGNTYRV, FF5 : CTSRNRCNDQ) of FN repeats were synthesized based on primary and tertiary human plasma FN structures (FINC-HUMAN: P02751). Each peptide was loaded in 15 x 15 mm fibrous alginate dressings, and the release kinetics of the peptides was evaluated using trinitrobenzene sulfonic acid (TNBSA) for 144 hours.
Two full-thickness cutaneous wounds were prepared on the dorsal skin of each 75 diabetes induced rats. Each wound was divided into FF3-loaded alginate dressing group, FF5-loaded alginate dressing group, alginate dressing group and negative control group. Two rats were sacrificed at day 0, and 24 rats were sacrificed at day 3, day 7 and day 14, respectively. The wound closure rate, inflammation degree, expression of TGF-Ξ²1 and hydroxyproline content were evaluated.
Results
Both FF3 and FF5 peptides were released rapidly within the first 24 hours. Regarding the wound closure rate, FF3-loaded dressing treated wounds closed significantly faster than other wounds at day 3. At day 7, both FF3- & FF5-loaded dressing treated wounds showed more wound closure than the alginate dressing treated group and the negative control group. At day 14, only negative control group showed delayed wound closure over the other groups. And at day 14, FF3- & FF5- loaded dressing treated wounds demonstrated less inflammatory cells infiltration than alginate dressing treated and negative group wounds. TGF-Ξ²1 positive cells were more abundant in FF3-, FF5-treated alginate dressing treated wound than negative control wounds at day 3 and 14. At day 7, FF3- & FF5- treated wounds showed more TGF-Ξ²1 positive cells than in alginate dressing treated wounds and negative control wounds. At last, the hyrdroxyproline contents in the FF3, FF5 group were higher than in the alginate dressing treated group and negative control group at day 7 and day 14.
Conclusions
Topical application of fibrin-binding domain synthetic oligopeptides from FN resulted in acceleration of full-thickness cutaneous wound healing in diabetic rats. Enhancement of TGF-Ξ²1 expression in fibrin-binding domain synthetic oligopeptides treated wounds seems to be a contributing factor or possible mechanism for the improvement of diabetic skin wound healing.Docto
λμμ(Moving Image)μ μ‘°νμ νΈμ§κΈ°λ² κ°λ°μ ν΅ν μν μ°κ΅¬
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :μ°μ
λμμΈκ³Ό μκ°λμμΈμ 곡,2000.Maste
κ³Όν νλμμμ λͺ¨νκ³Ό λͺ¨νν : μ ꡬ κΈ°ν λͺ¨νμ μ€μ¬μΌλ‘
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :νλκ³Όμ κ³Όνμ¬ λ° κ³Όνμ² ν,2002.Maste
(The) prognostic value of serum CA 125 in endometrial cancer.
μκ³Όνμ¬μ
λ¨/μμ¬[νκΈ]
μκΆλ΄λ§μμ λ―Έκ΅μμμ κ°μ₯ νν λΆμΈμμΌλ‘, 1997λ
ν ν΄ λμ 37,400λͺ
μ΄ μ νμΌλ‘ λ±λ‘νμκ³ 6,400λͺ
μ΄ μλͺ
μ μμ κ²μΌλ‘ λ³΄κ³ λμλ€. μ°λ¦¬ λλΌμμλ μκΆκ²½λΆμμ΄ κ°μ₯ νν λΆμΈμμ΄μ§λ§, μꡬν λμ΄ κ°λ μν μμμ λ°λΌ μ μ°¨ μκΆλ΄λ§μμ μ€μμ±μ΄ λλλκ³ μλ€. μ’
μνμ§λ¬Όμ§μΈ Cancer Antigen 125 (CA 125)λ κ³ λΆμλμ λΉλ¨λ°±μΌλ‘ μ΄λ£¨μ΄μ§ μ₯μ‘μ± λμμ μΈν¬μ£Ό OVCA 433μ λν λ¨μΌ ν΄λ‘ ν체λ‘μ, Bastλ±μ΄ 35U/γ λ―Έλ§μ μ μ λ²μλ‘ μ μν μ΄λ μ΄ μΈ‘μ μΉλ₯Ό κΈ°μ€μΌλ‘ μκΆλΆμκΈ° μ’
μμ μ
μ± μ 무, λΉμ μ‘μ± λμμμμμ μνμΈμ, λλ λμμμμ νμμλ²μ λν λ°μμ λλ₯Ό μΈ‘μ νκΈ° μνμ¬ μ°μ¬μ Έ μλ€.
μκΆλ΄λ§μμμλ λμμμ CA 125μ²λΌ μ μ©νκ² μ°μΌ μ μλ μ’
μνμ§λ¬Όμ§μ λν μ°κ΅¬κ° λ§μ§ μλ€. μ μ μκΆλ΄λ§ μ‘°μ§κ³Ό μκΆλ΄λ§μ μ‘°μ§ λͺ¨λμμ CA 125κ° λ°νλλ€λ λ³΄κ³ λ₯Ό κΈ°μ΄λ‘ λ³Έ μ°κ΅¬μμλ μκΆλ΄λ§μ νμμ μμ μ νκ°μ μμ΄μ CA 125μ μμλ₯Όμμλ³΄κ³ μ΄μ λν μ μ ν κΈ°μ€μΉλ₯Ό μ€μ νκ³ μ νμλ€. μ΄μκ³Ό κ°μ λͺ©μ νμ 1995λ
3μλΆν° 2001λ
3μκΉμ§ μ°μΈλνκ΅ μκ³Όλν μ°λΆμΈκ³Όμμ μκΆλ΄λ§μμΌλ‘ μ§λ¨ λ°μ μμ μ λ³κΈ° κ²°μ μ νκ³ μ΄ν μΆμ κ΄μ°° μ€μΈ 119λͺ
μ νμλ€μ μ무기λ‘μ κΈ°μ΄λ‘ νν₯μ
μ°κ΅¬λ₯Ό μν νμλ€. CA 125μ μνμΈμλ‘μμ κ°μΉλ λ€λ₯Έ μνμΈμλ€κ³Όμ μ°κ΄μ±, μμ μ견μ μμΈ‘μ λ, 5λ
μμ‘΄λ₯ λ±μ ν΅νμ¬ νκ°νμμΌλ©°, κ·Έ κΈ°μ€μΉλ κΈ°μ‘΄μ μλ €μ Έ μλ 35U/γ, λλ 20U/γλ₯Ό κ·Όκ±°λ‘ κ°κ°μ λ―Όκ°λ, νΉμ΄λ, μμμ±λ₯ , μμμ±λ₯ μ ꡬνμ¬ λΆμνμλ€. νμμ νμ² CA 125λ ν¨μ λ©΄μ λΆμ λ°©λ² (enzyme immunoassay; Elecsys 2010, Roche Ltd., Basel, Switzerland)μ μ΄μ© νμλ€.
μ°κ΅¬ κ²°κ³Ό μκΆλ΄λ§μμμ CA 125λ λΆλν μμλ³λ¦¬νμ μνμΈμμΈ μ§νλ λ³κΈ°, μκΆκ·ΌμΈ΅ λλ μκΆκ²½λΆ μΉ¨λ², λμ μ‘°μ§νμ λΆνλμ μ°κ΄μ΄ μλ κ²μΌλ‘ λνλ¬μΌλ©°(p<0.05), μμ μ견μ μμΈ‘ν μ μλ μμ μ κ²μ¬νλͺ©μΌλ‘λ μ기곡λͺ
촬μ, νμ² CA 125, μ§μ΄μνκ° μμκ³ , CA 125β₯20U/γκ° λ―Όκ°λμ μμμ±λ₯ μΈ‘λ©΄μμ λ³Ό λ κΈ°μ‘΄μ κΈ°μ€μΉμΈ CA 125β₯35U/γ λ³΄λ€ λ μλ―Έκ° μμκ³ , CA 125β₯20U/γλ 5λ
μμ‘΄λ₯ κ³Ό μ μν κ΄κ³λ₯Ό 보μλ€(p<0.05).
μκΆλ΄λ§μμμ CA 125λ μνμΈμλ‘μμ μμμ κ°μΉκ° μμΌλ―λ‘ κΈ°μ΄ κ²μ¬μ μ΄λ₯Ό ν¬ν¨μμΌ νμμ μνλ₯Ό μμΈ‘νκ³ μΉλ£ λ°©λ²μ κ°λ³ννλλ° μ΄μ©ν μ μκ² λ€. νΉν νκ²½ μ¬μ±μ΄ λλ€μμΈ μκΆλ΄λ§μμμλ νμ² CA 125κ° κΈ°μ‘΄μ 35U/γκ° μλ 20U/γ μ΄μμΌλ‘μΈ‘μ λμμ λλ₯Ό μλ―Έ μκ² μ¦κ°λ κ²μΌλ‘ κ°μ£Όνμ¬μΌκ² λ€. μκΆλ΄λ§μμμ μΆμ μΈμλ‘μμ CA 125μ κ°μΉλ λ λ§μ νμλ€μ λμμΌλ‘ μ°κ΅¬λμ΄μ ΈμΌν κ²μΌλ‘ μ¬λ£λλ€.
[μλ¬Έ]
Endometrial cancer is the most common gynecologic cancer in the United States, and in the year 1997, about 37,400 patients were newly registered in the cancer registry and 6,400 patients died due to this disease. In Korea, the most common gynecologic cancer is still the uterine cervix cancer, but the incidence of endometrial cancer is rising with the changes in life style and there is a growing academic interest about this disease. The tumor marker Cancer Antigen 125 (CA 125) is a monoclonal antibody towards the serous ovarian cancer cell line OVCA 433. Since the first report by Bast et al. on CA 125, it has been used as the marker of adnexal tumor, the prognostic factor of nonmucinous ovarian malignancy, and the follow up marker of ovarian malignancy during chemotherapy. Unlike ovarian malignancy, not many studies have been undertaken about the significance of tumor
markers in endometrial cancer. As it has been reported, CA 125 is found in normal and malignant endometrium. Based on these reports, the prognostic value of serum CA 125 sampled before the staging operation and the right CA 125 cut-off level in endometrial cancer was evaluated. Enzyme immunoassay (Elecsys 2010; Roche Ltd., Basel, Switzerland) was used for the measurement of serum CA 125.
Medical charts of 119 endometrial cancer patients diagnosed and surgically treated at the Department of Obstetrics and Gynecology, Yonsei University College of Medicine from March 1995 to March 2001 were reviewed. The prognostic value of CA
125 was evaluated by comparing it to other established prognostic factors of endometrial cancer such as myometrial invasion, cervix extension, tumor size, and grossly invasive disease. Informations that could be obtained prior to the surgical staging procedure such as magnetic resonance imaging, transvaginal ultrasonography,
CA 125 level, histologic grade, and age were evaluated for their predictability of surgical findings suggesting extensive endometrial cancer needing lymphadenectomy. The difference of five year survival according to the level of CA 125 was also
evaluated. The right cut-off value of CA 125 in the endometrial cancer patients who were mostly postmenopausal women was estimated.
The result of this study implies that the level of presurgically taken serum CA 125 level correlated well with the established prognostic factors of endometrial cancer. CA 125 was one of the information that could be obtained prior to the surgical staging for predicting extensive endometrial cancer, and it could be
correlated with the 5 year survival. CA 125β₯20U/γ had a higher sensitivity and lower false negative rate in predicting extensive endometrial cancer compared to the conventionally used level of CA 125β₯35U/γ.
CA 125 has a prognostic value in predicting the extensive endometrial cancer needing lymphadenectomy. It might be included in the baseline study of endometrial cancer for predicting the prognosis and individualizing the treatment modality. CA 125β₯20U/γ might be considered as the cut-off level in endometrial cancer for a better sensitivity and false negative rate. The significance of CA 125 as a follow up marker in endometrial cancer awaits further studies in the future.ope
Muscle regeneration with tooth-derived primary culture cells
μΉμνκ³Ό/μμ¬λ³Έ μ°κ΅¬λ κ΅μ μΉλ£ μ λ°κ±°λλ μꡬ μꡬμΉμ μΌμ°¨ λ°°μ μΈν¬λ₯Ό μ΄μ©νμ¬ κ·Όμ‘μΈν¬λ‘μ λΆνλ₯Ό μ λνκ³ , μ΄λ₯Ό λ§μ°μ€ μ체λ΄μ μ μ©νμ¬ κ·Όμ‘ μ¬μ ν¨κ³Όλ₯Ό μμλ³΄κ³ μ νμλ€. λ°μΉλ μꡬμΉμ μΉμ£ΌμΈλ λ° μΉμ μ‘°μ§μΌλ‘λΆν° νλν μΈν¬λ₯Ό DNA νλ©νΈν μ½λ¬ΌμΈ 5-aza-2Β΄-deoxycytidineλ‘ μ²λ¦¬ν ν κ·Όμ‘μΈν¬ λΆν μ λλ₯Ό νμΈνμλ€. λ§μ°μ€ κ·Όμ‘ μμ λ° μ¬μ λͺ¨λΈμ μ΄μ©νμ¬ κ·Όμ‘μΈν¬λ‘ λΆν μ λλ μΉμμΈν¬λ₯Ό μ₯λ΄μ§κ·Όκ³Ό κ΅κ·Όμ μ΄μν ν μ‘°μ§νμ μΌλ‘ νκ°νκ³ , μ΄μλ μΉμ μΈν¬λ₯Ό μΆμ ν κ²°κ³Ό λ€μκ³Ό κ°μ κ²°λ‘ μ μ»μλ€.1. μΉμ£ΌμΈλ λ° μΉμμΈν¬λ κ·Όμ‘λΆν μ λ λ°°μ§ λ¨λ
μΌλ‘λ κ·Όμ‘μΈν¬ λΆν μ λκ° λμ§ μμμΌλ, 5-aza-2Β΄-deoxycytidine μ μ²λ¦¬μ κ·Όμ‘λΆν μ λ λ°°μ§λ₯Ό μ¬μ©ν¨μΌλ‘μ¨ κ·Όμ‘ νΉμ΄ λ¨λ°±μ§μΈ desmin μμ±μ myotube κ΅¬μ‘°λ‘ λΆνλμλ€. μΉμ£ΌμΈλμΈν¬μ λΉν΄ μΉμμΈν¬μμ λ κ΅΅κ³ λ§μ μμ myotubeκ° λΆνλμλ€.2. μΉμμΈν¬λ 5-aza-2Β΄-deoxycytidine μ μ²λ¦¬λ‘ κ·Όμ‘λΆν μ λ ν desmin λ° myogenin λ°νμ΄ μ¦κ°ν λ°λ©΄, μΉμ£ΌμΈλ μΈν¬μμλ κ·Όμ‘ λΆν μ λ ν myogeninμ λ°νμ μ€νλ € κ°μνμλ€.3. λ§μ°μ€ κ·Όμ‘ μ¬μ λͺ¨λΈμ H&E (hematoxylin and eosin) μΌμ κ²°κ³Ό, κ·Όμ‘λΆν μ λλ μΉμμΈν¬λ₯Ό μ£Όμ
ν κ΅°μ κ²½μ° λμ‘°κ΅°μ λΉν΄ μ‘°μ§νμ μΌλ‘ κ·Όμ‘μ¬μ ν¨κ³Όκ° μμμ΄ νμΈλμλ€.4. λ§μ°μ€ κ·Όμ‘ μ¬μ λͺ¨λΈμ μ΄μ©νμ¬ μ₯λ΄μ§κ·Όμ μ£Όμ
λ μΉμμΈν¬λ₯Ό μΆμ ν κ²°κ³Ό λ§μ°μ€ κ·Όμ‘ μ‘°μ§μΌλ‘μ μμ°©μ΄ νμΈλμλ€.5. λ§μ°μ€ κ·Όμ‘ μ¬μ λͺ¨λΈμ λ©΄μνκ΄ λΆμ κ²°κ³Ό, κ·Όμ‘λΆν μ λλ μΉμμΈν¬λ₯Ό μ£Όμ
ν κ΅°μ κ²½μ°, PBSλ₯Ό μ£Όμ
ν λμ‘°κ΅°μ λΉν΄ μμ μ μ¬μλλ μ μκ·Όμ‘μ νμ§μμΈ eMHC (embryonic myosin Heavy chain) λ° νκ΄λ΄νΌμΈν¬ νμ§μμΈ CD31 λ°νμ΄ μ°μΈνμλ€.λ°λΌμ μΉμμΈν¬λ₯Ό μ΄μ©ν μ체 λ΄ μ΄μ μ°κ΅¬κ° μΆ©λΆν λ·λ°μΉ¨ λλ€λ©΄ μ
μλ©΄ μ°μ‘°μ§ μ¬μ λΆμΌμ λν νμ© κ°λ₯μ±μ κΈ°λν μ μμ κ²μ΄λ€.ope
λ¬λΌνΌμ½λΌμ Canti di prigioniaμ κ΄ν λΆμ λ° κ³ μ°°
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :μμ
κ³Ό μ곑μ 곡,1995.Maste
Effect of non-surgical therapy combined with overhanging margin removal by Profin system in chronic periodontitis patient
Thesis(masters) --μμΈλνκ΅ λνμ :μΉμνκ³Ό(μΉμ£Όκ³Όνμ 곡),2008. 8.Maste
The Study on men`s jacket block according to somatotype
νμλ
Όλ¬Έ(λ°μ¬)--μμΈλνκ΅ λνμ :μλ₯νκ³Ό,2000.Docto